A computer tool uses MRI scans to sort brain tumor risk
Original title: Deep learning-based cross-attention fusion of multimodal MRI for survival prediction and risk stratification in IDH-wildtype glioblastoma: a multicenter study.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This used old scans from real patients, and it must be tested in new patients before doctors can use it.
The short version
Researchers built a computer tool that reads MRI scans to help guess who faces higher risk.
What was studied. Researchers used scans and records from 386 adults with a brain tumor called IDH gene change: A small change in a tumor's IDH gene. It is the first thing your team looks at when naming an adult glioma, and it can affect which treatments are offered. Your pathology report says whether your tumor has it. See the glossary wildtype glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary. The people came from three groups, with 226, 62, and 98 patients. The team tested computer programs that read a few kinds of MRI scans taken before surgery.
What they found. The new way of blending the scans did a little better than the older ways. But the gap was small, and it could have been due to chance. When the team added basic patient facts to the scan results, the tool sorted people into higher risk and lower risk groups. It did this in all three groups of patients, though it worked less well in some.
What this means, and what it doesn't
What it could mean: One day, doctors may get a sense of risk from plain MRI scans. That could help when lab tests on the tumor are missing or not complete. It could help with planning care and talking about what may lie ahead.
What it doesn't mean: This is not a treatment. It is not a cure, and it does not change how anyone is treated today. The team looked back at scans and records that were already collected. The tool cannot say what will happen to one person. The researchers say it must be tested in new patients before doctors use it.
Source: PubMed, August 24, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.